Lolawest

Lolawest is a hypoammoniemic agent containing the stable salt L-ornithine L-aspartate (LOLA), developed and marketed by Western Pharmaceutical Industries. It is indicated for the treatment of hyperammonemia associated with acute and chronic liver diseases, such as liver cirrhosis and hepatic encephalopathy. The drug functions by providing substrates for two key ammonia detoxification pathways: the urea cycle in the liver (via ornithine) and glutamine synthesis in the liver, muscle, and brain (via aspartate). By lowering blood ammonia levels, Lolawest helps mitigate the neurotoxic effects of ammonia in patients with severe liver impairment. It is available in both oral sachet and injectable ampoule formulations.

Brand names

Lolawest

Other names

L-ornithine L-aspartateLOLA